GAP Supply Act Growing America’s Pharmaceutical Supply Act
To amend section 503B of the Federal Food, Drug, and Cosmetic Act to enhance the ability of outsourcing facilities to mitigate drug shortages by allowing a short-term period to continue supplying the market after a drug is in shortage.
HB7528, also known as the Growing America’s Pharmaceutical Supply Act, aims to address drug shortages by allowing outsourcing facilities to temporarily continue supplying the market even after a drug is officially in shortage. This bill seeks to amend section 503B of the Federal Food, Drug, and Cosmetic Act to provide more flexibility for these facilities, which can help ensure that essential medications remain available during critical times.
The bill would primarily affect outsourcing facilities that manufacture drugs, as well as patients and healthcare providers who rely on these medications. By allowing a short-term extension to continue supplying drugs in shortage, the bill hopes to mitigate the impact of shortages on patient care and healthcare systems.
As of February 12, 2026, HB7528 was introduced in the House and referred to the House Committee on Energy and Commerce. This is the first step in the legislative process, and the bill is currently under review by the committee. Key actions so far include its introduction and referral to the appropriate committee for further consideration.
